Cystatin C as a biomarker of chronic kidney disease: latest developments
Introduction Chronic kidney disease (CKD) is common, occurring in over 10% of individuals globally, and is increasing in prevalence. The limitations of traditional biomarkers of renal dysfunction, such as serum creatinine, have been well demonstrated in the literature. Therefore, augmenting clinical...
Wedi'i Gadw mewn:
| Prif Awduron: | , , |
|---|---|
| Fformat: | Revisão |
| Iaith: | Saesneg |
| Cyhoeddwyd: |
2020
|
| Mynediad Ar-lein: | https://doi.org/10.1080/14737159.2020.1768849 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|